2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Study Population, Human, Adult, Animal Model
PAPER

1439 Defining the mechanism of HMGB3 regulated leukemia proliferation

Samantha A Swenson, PhD, Jackson Courville2, Arjun Dhir, PhD3, Isabelle S Weber4, Isabella Caranna5, Riley AW Watkins6, Kasidy K Dobish, PhD7, Peng Xiao8, Adrian R Black, PhD9, Shannon M. Buckley, PhD10, R. Katherine Hyde, PhD11
1 University of Nebraska Medical Center, Omaha, Nebraska, United States
2 University of Nebraska Medical Center, Omaha, Nebraska, United States
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Nebraska Medical Center, Omaha, Nebraska, United States
4 University of Nebraska Medical Center, Omaha, Nebraska, United States, University of Nebraska Omaha, Omaha, Nebraska, United States
5 Doane University, Crete, Nebraska, United States, University of Nebraska Medical Center, Omaha, Nebraska, United States
6 University of Nebraska Medical Center, Omaha, Nebraska, United States
7 University of Nebraska Medical Center, Omaha, Nebraska, United States, University of Utah Huntsman Center, Salt Lake City, Utah, United States
8 University of Nebraska Medical Center, Omaha, Nebraska, United States
9 University of Nebraska Medical Center, Omaha, Nebraska, United States
10 University of Utah Huntsman Center, Salt Lake City, Utah, United States
11 University of Nebraska Medical Center, Omaha, Nebraska, United States

Acute Myeloid leukemia (AML) is the deadliest form of leukemia and genetic heterogeneity makes current treatments ineffective for many patients. Even patients who initially respond to therapy can relapse and become unresponsive to treatment. This highlights the need to identify new therapies that can target AML regardless of the initiating mutation. In pursuit of this goal, we identified the chromatin binding factor high mobility group box 3 (HMGB3) as a potential therapeutic target. HMGB3 is primarily expressed in the nucleus of hematopoietic stem cells (HSCs) and regulates the balance between immature and mature blood cells. Previous work in vitro has implied a role for HMGB3 in leukemia stem cells as well; however, the mechanism remains to be determined.

In initial studies, we found that HMGB3 protein is markedly increased as compared to healthy HSCs in a variety of leukemia cell lines and AML patient samples regardless of the subtype. Knockdown (KD) of HMGB3 in the human AML cell lines reduced growth rate, accompanied by a significant decrease in proliferation. KD cells also show cell cycle arrest in G0/G1. Colony assays of control and KD cells showed no difference in colony number, although colonies from KD cells were notably smaller supporting our finding that loss of HMGB3 causes a decrease in leukemia cell proliferation. To determine if HMGB3 has a similar role in models that more closely resemble human disease, we used human bone marrow organoids (hBMOs) and xenograft mice. HMGB3 KD cells engrafted into hBMOs showed a decreased rate of proliferation and xenograft tumors from mice transplanted with KD cells grew slower and were significantly smaller compared to those from wildtype cells. These results further support a role for HMGB3 in regulating leukemia cell proliferation.

To identify potential mechanisms of HMGB3 activity, we performed whole transcriptome sequencing of control and HMGB3 KD MOLM13 cells and identified 131 differentially expressed genes. Gene Ontology analysis showed that the downregulated genes were associated with glycolysis and MAPK signaling. We also found a reduction in the protein levels of key rate-limiting enzymes of the glycolytic pathway and decreased glucose uptake and lactic acid release in KD cells. We also saw a decrease in activated, but not total abundance of several kinases in the MAPK signaling pathway. Additionally, we found a reduction in activated, but not total, AKT and the downstream target of mTOR, P70S6K, in KD cells. Taken together, these data indicate that loss of HMGB3 downregulates glycolysis and MAPK-AKT-mTOR activation, providing a potential mechanism for HMGB3's control of proliferation.

Our finding that HMGB3 is required for the activation, but not total abundance, of signaling pathways raises the possibility that HMGB3 may have cytosolic activities, as shown for other HMGB family members. To test this, we compared HMGB3 localization in primary patient AML samples and CD34+ cells from healthy individuals and found that in AML, HMGB3 accumulates in the cytoplasm in distinct puncta. Leukemia cells are known to have higher reactive oxygen species (ROS) levels than healthy cells, and redox modification is a known regulator of cytoplasmic localization. To test if HMGB3 localization could be susceptible to redox regulation, we treated leukemia cells with increasing doses of oxidizing agents. We found higher oxidative conditions resulted in oxidation of HMGB3. HMGB3 contains three conserved cysteines, residues highly susceptible to ROS. To determine if redox modulation of these cysteines affects HMGB3 localization, we mutated them to mimic reduced and oxidized forms of the protein. In contrast to the wildtype protein, which is localized to the nucleus, mutants mimicking oxidized HMGB3 were entirely cytosolic. We also found that HMGB3 KD cells re-expressing oxidized mimetics are unable to rescue leukemia cell growth. Our observation that cytosolic HMGB3 appears to form distinct puncta raises the possibility that it is actively secreted. In fact, by ELISA assays, we found that HMGB3 is secreted from leukemia cells in vitro. This suggests that HMGB3 may be regulating signaling in a paracrine manner through its extracellular form in a redox dependent manner.

Collectively, our results indicate that HMGB3 is an important regulator of leukemia cell proliferation and a potential therapeutic target for the development of more effective treatments for patients with leukemia.

Samantha A Swenson, PhD: No relevant conflicts of interest to declare.